Feds Urge Vaccination as ‘Tripledemic’ Hits More Americans
Vaccination will be key to keeping patients healthy through the winter holidays
Diagnosis & Disease Information
Study Looks at Extent of Residual Lung Abnormalities After COVID-19 Hospitalization
Posthospitalization prevalence of residual lung abnormalities estimated at 11.7 percent in sensitivity analyses
AAP Releases “Choosing Wisely” Recommendations for Pediatric Emergency Medicine
As part of the Choosing Wisely campaign, the American Academy of Pediatrics (AAP) has released a new list of 5 tests and procedures commonly ordered in pediatric emergency medicine that physicians and patients should question. Choosing Wisely is an American Board of Internal Medicine (ABIM) Foundation initiative that aims to promote discussions between clinicians and…
Extended-Release Morphine Does Not Reduce Breathlessness in COPD
One week of extended-release morphine does not significantly reduce the intensity of worst breathlessness
Exacerbations Risk Exists for Patients With All Levels of Asthma Control/Severity
The researchers analyzed 351,870 US patients at least 12 years of age from the IBM MarketScan databases who received SABA for asthma from 2010 to 2017.
Researchers Link Smell Loss, Disease Burden, and Dupilumab Efficacy in CRSwNP
Greater disease burden in chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with increased loss of smell severity. Outcomes of CRSwNP were significantly improved with dupilumab, regardless of loss of smell severity at baseline. These are among the post-hoc analysis findings presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific…
Use of Biologics Reduces Exacerbations, Emergency Visits in Pediatric Asthma
Investigators assessed a real-world pediatric patients with asthma who used biologic therapy to identify their response to prescribed biologics and reasons for discontinuation of therapy as well as to characterize other attributes of this population.
AAP Issues Updated Guidance on Palivizumab Use for the 2022-2023 RSV Season
For regions with high levels of RSV disease activity in the fall and winter, the AAP supports the use of more than 5 consecutive doses of palivizumab to eligible infants.
Certain Clinical Markers May Predict AERD in Patients With CRSwNP
Researchers conducted a retrospective, observational study of 177 patients with CRSwNP from January 1, 2016, to December 29, 2021.
Uncontrolled Asthma in Hispanic/Latino Patients Improved With Tezepelumab
Investigators assessed the annualized asthma exacerbation rate (AAER) and the annualized rate of asthma exacerbations requiring hospitalization over 52 weeks.
